237 related articles for article (PubMed ID: 31033025)
21. Extensive preclinical evaluation of lutetium-177-labeled PSMA-specific tracers for prostate cancer radionuclide therapy.
Ruigrok EAM; van Vliet N; Dalm SU; de Blois E; van Gent DC; Haeck J; de Ridder C; Stuurman D; Konijnenberg MW; van Weerden WM; de Jong M; Nonnekens J
Eur J Nucl Med Mol Imaging; 2021 May; 48(5):1339-1350. PubMed ID: 33094433
[TBL] [Abstract][Full Text] [Related]
22. Targeting of the Cholecystokinin-2 Receptor with the Minigastrin Analog
Sauter AW; Mansi R; Hassiepen U; Muller L; Panigada T; Wiehr S; Wild AM; Geistlich S; Béhé M; Rottenburger C; Wild D; Fani M
J Nucl Med; 2019 Mar; 60(3):393-399. PubMed ID: 30002107
[TBL] [Abstract][Full Text] [Related]
23. A novel 177Lu-labeled porphyrin for possible use in targeted tumor therapy.
Das T; Chakraborty S; Sarma HD; Banerjee S; Venakatesh M
Nucl Med Biol; 2010 Jul; 37(5):655-63. PubMed ID: 20610170
[TBL] [Abstract][Full Text] [Related]
24. Development of a (68)Ga-peptide tracer for PET GnRH1-imaging.
Zoghi M; Jalilian AR; Niazi A; Johari-Daha F; Alirezapour B; Ramezanpour S
Ann Nucl Med; 2016 Jul; 30(6):400-8. PubMed ID: 27083468
[TBL] [Abstract][Full Text] [Related]
25. Bulk Scale Formulation of Therapeutic Doses of Clinical Grade Ready-to-Use
Mathur A; Prashant V; Sakhare N; Chakraborty S; Vimalnath KV; Mohan RK; Arjun C; Karkhanis B; Seshan R; Basu S; Korde A; Banerjee S; Dash A; Sachdev SS
Cancer Biother Radiopharm; 2017 Sep; 32(7):266-273. PubMed ID: 28910148
[TBL] [Abstract][Full Text] [Related]
26.
Vats K; Satpati AK; Sharma R; Sarma HD; Satpati D; Dash A
J Pharm Biomed Anal; 2018 Apr; 152():173-178. PubMed ID: 29414010
[TBL] [Abstract][Full Text] [Related]
27. Preparation of
Pandey U; Kameswaran M; Gamre N; Dash A
J Labelled Comp Radiopharm; 2019 Apr; 62(4):158-165. PubMed ID: 30663095
[TBL] [Abstract][Full Text] [Related]
28. DOTA-MGS5, a New Cholecystokinin-2 Receptor-Targeting Peptide Analog with an Optimized Targeting Profile for Theranostic Use.
Klingler M; Summer D; Rangger C; Haubner R; Foster J; Sosabowski J; Decristoforo C; Virgolini I; von Guggenberg E
J Nucl Med; 2019 Jul; 60(7):1010-1016. PubMed ID: 30530828
[TBL] [Abstract][Full Text] [Related]
29. DOTA conjugate with an albumin-binding entity enables the first folic acid-targeted 177Lu-radionuclide tumor therapy in mice.
Müller C; Struthers H; Winiger C; Zhernosekov K; Schibli R
J Nucl Med; 2013 Jan; 54(1):124-31. PubMed ID: 23236020
[TBL] [Abstract][Full Text] [Related]
30. Theranostic Perspectives in Prostate Cancer with the Gastrin-Releasing Peptide Receptor Antagonist NeoBOMB1: Preclinical and First Clinical Results.
Nock BA; Kaloudi A; Lymperis E; Giarika A; Kulkarni HR; Klette I; Singh A; Krenning EP; de Jong M; Maina T; Baum RP
J Nucl Med; 2017 Jan; 58(1):75-80. PubMed ID: 27493272
[TBL] [Abstract][Full Text] [Related]
31. Synthesis, Radiolabeling, and Preclinical Evaluation of
Okarvi SM; Al-Jammaz I
Cancer Biother Radiopharm; 2022 Jun; 37(5):372-383. PubMed ID: 35325547
[No Abstract] [Full Text] [Related]
32. Targeted radiotherapy of prostate cancer with a gastrin-releasing peptide receptor antagonist is effective as monotherapy and in combination with rapamycin.
Dumont RA; Tamma M; Braun F; Borkowski S; Reubi JC; Maecke H; Weber WA; Mansi R
J Nucl Med; 2013 May; 54(5):762-9. PubMed ID: 23492884
[TBL] [Abstract][Full Text] [Related]
33. An assessment tumor targeting ability of (177)Lu labeled cyclic CCK analogue peptide by binding with cholecystokinin receptor.
Cho EH; Lim JC; Lee SY; Jung SH
J Pharmacol Sci; 2016 Jul; 131(3):209-14. PubMed ID: 27430985
[TBL] [Abstract][Full Text] [Related]
34. Targeted antisense radiotherapy and dose fractionation using a (177)Lu-labeled anti-bcl-2 peptide nucleic acid-peptide conjugate.
Liu D; Balkin ER; Jia F; Ruthengael VC; Smith CJ; Lewis MR
Nucl Med Biol; 2015 Sep; 42(9):704-10. PubMed ID: 26081917
[TBL] [Abstract][Full Text] [Related]
35. DOTA-PESIN, a DOTA-conjugated bombesin derivative designed for the imaging and targeted radionuclide treatment of bombesin receptor-positive tumours.
Zhang H; Schuhmacher J; Waser B; Wild D; Eisenhut M; Reubi JC; Maecke HR
Eur J Nucl Med Mol Imaging; 2007 Aug; 34(8):1198-208. PubMed ID: 17262215
[TBL] [Abstract][Full Text] [Related]
36. [177Lu-DOTA(0),Tyr3] octreotate for somatostatin receptor-targeted radionuclide therapy.
de Jong M; Breeman WA; Bernard BF; Bakker WH; Schaar M; van Gameren A; Bugaj JE; Erion J; Schmidt M; Srinivasan A; Krenning EP
Int J Cancer; 2001 Jun; 92(5):628-33. PubMed ID: 11340564
[TBL] [Abstract][Full Text] [Related]
37. Characterization and evaluation of DOTA-conjugated Bombesin/RGD-antagonists for prostate cancer tumor imaging and therapy.
Stott Reynolds TJ; Schehr R; Liu D; Xu J; Miao Y; Hoffman TJ; Rold TL; Lewis MR; Smith CJ
Nucl Med Biol; 2015 Feb; 42(2):99-108. PubMed ID: 25459113
[TBL] [Abstract][Full Text] [Related]
38. The preclinical study of
Molavipordanjani S; Mousavi T; Khorramimoghaddam A; Talebpour Amiri F; Abedi SM; Hosseinimehr SJ
Ann Nucl Med; 2023 Jul; 37(7):400-409. PubMed ID: 37115407
[TBL] [Abstract][Full Text] [Related]
39. Pegylated Arg-Gly-Asp peptide: 64Cu labeling and PET imaging of brain tumor alphavbeta3-integrin expression.
Chen X; Hou Y; Tohme M; Park R; Khankaldyyan V; Gonzales-Gomez I; Bading JR; Laug WE; Conti PS
J Nucl Med; 2004 Oct; 45(10):1776-83. PubMed ID: 15471848
[TBL] [Abstract][Full Text] [Related]
40. Clinical Dose Preparation of [
Menon SR; Mitra A; Chakraborty A; Tawate M; Sahu S; Rakshit S; Gaikwad S; Dhotre G; Damle A; Banerjee S
Cancer Biother Radiopharm; 2022 Jun; 37(5):384-402. PubMed ID: 35575711
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]